# Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

> **NCT03624946** · PHASE1 · COMPLETED · sponsor: **Emergent BioSolutions** · enrollment: 30 (actual)

## Conditions studied

- Zika Virus Infection
- Zika Virus Disease

## Interventions

- **BIOLOGICAL:** Zika Virus Immune Globulin (ZIKV-IG)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03624946
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-27
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-03-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624946, "Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03624946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*